14-515
MAP激酶1/Erk1蛋白，失活，50 g
Unactive, N-terminal GST-tagged, recombinant, full-length, human MAP Kinase 1/Erk1, for use in Kinase Assays.
产品名称
MAP激酶1/Erk1蛋白，失活，50 g, Unactive, N-terminal GST-tagged, recombinant, full-length, human MAP Kinase 1/Erk1, for use in Kinase Assays.
biological source
human
recombinant
expressed in E. coli
mol wt
Mw 70 kDa
manufacturer/tradename
Upstate®
technique(s)
activity assay: suitable (kinase)
NCBI accession no.
UniProt accession no.
shipped in
dry ice
Quality Level
Analysis Note
通过体外MBP底物的磷酸化进行常规评估
Application
研究子类别
肥胖症
代谢紊乱
肥胖症
代谢紊乱
研究类别
代谢
代谢
Biochem/physiol Actions
蛋白质靶标：MAPK1
靶标亚家族：CMGC
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
N末端GST标记的重组全长人MAP激酶1/Erk1
产品来源：在大肠埃希菌中表达
Other Notes
比活相关数据，请参阅检验报告以获取该酶的单独批次。
Physical form
谷胱甘肽琼脂糖
Preparation Note
在-20°C下可保存6个月
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Warning
hcodes
Hazard Classifications
Skin Sens. 1
存储类别
10 - Combustible liquids
wgk
WGK 2
Ivana Yen et al.
Cancer cell, 34(4), 611-625 (2018-10-10)
Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors. In combination drug screens, MEK and PI3K inhibitors synergized with pan-RAF inhibitors
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持